Potentially Resectable Stage II/IIIa NSCLC
1 clinical trials · Condition
◉ Watch Potentially Resectable Stage II/IIIa NSCLC
| Record | Firm | Date |
|---|---|---|
| Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC (NCT03694236) | Yonsei University | 2019-02-12 |
Track Potentially Resectable Stage II/IIIa NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.